SEARCH

SEARCH BY CITATION

REFERENCES

  • Attias D, Stheneur C, Roy C, Collod-Béroud G, Detaint D, Faivre L, Delrue MA, Cohen L, Francannet C, Béroud C, Claustres M, Iserin F, Khau Van Kien P, Lacombe D, Le Merrer M, Lyonnet S, Odent S, Plauchu H, Rio M, Rossi A, Sidi D, Steg PG, Ravaud P, Boileau C, Jondeau G. 2009. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 120: 25412549.
  • Baetens M, Van Laer L, De Leeneer K, Hellmans J, De Schrijver J, Van De Voorde H, Renard M, Dietz H, Lacro RV, Menten B, Van Criekinge W, De Backer J, De Paepe A, Loeys B, Coucke PJ. 2011. Applying massive parallel sequencing to molecular diagnosis of Marfan and Loeys–Dietz syndrome. Hum Mutat. DOI: 10.1002/humu.21525 [Epub ahead of print].
  • Benedetto U, Melina G, Takkenberg JJ, Roscitano A, Angeloni E, Sinatra R. 2011. surgical management of aortic root disease in Marfan syndrome: A systematic review and meta-analysis. Heart 97: 955958.
  • Bentall H, De Bono A. 1968. A technique for complete replacement of the ascending aorta. Thorax 23: 338339.
  • Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. 2008. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 358: 27872795.
  • De Paepe A, Deitz HC, Devereux RB, Hennekem R, Pyeritz RE. 1996. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62: 417426.
  • Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, Stetten G, Meyers DA, Francomano CA. 1991. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352: 337339.
  • Dagoneau N, Benoist-Lasselin C, Huber C, Faivre L, Mégarbané A, Alswaid A, Dollfus H, Alembik Y, Munnich A, Legeai-Mallet L, Cormier-Daire V. 2004. ADAMTS10 mutations in autosomal recessive Weill–Marchesani syndrome. Am J Hum Genet 75: 801806.
  • Detaint D, Aegerter P, Tubach F, Hoffman I, Plauchu H, Dulac Y, Faivre LO, Delrue MA, Collignon P, Odent S, Tchitchinadze M, Bouffard C, Arnoult F, Gautier M, Boileau C, Jondeau G. 2010. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis 103: 317325.
  • Faivre L, Collod-Beroud G, Adès L, Arbustini E, Child A, Callewaert B, Loeys B, Binquet C, Gautier E, Mayer K, Arsian-Kirchner M, Grasso M, Beroud C, Hamroun D, Bonithon-Kopp C, Plauchu H, Robinson P, De Backer J, Coucke P, Francke U, Bouchot O, wolf J, Stheneur C, Hanna N, Detaint D, De Paepe A, Boileau C, Jondeau G. 2011. The new Ghent criteria for Marfan syndrome: What do they change? Clin Genet. DOI: 10.1111/j.1399-0004.2011.01703.x [Epub ahead of print].
  • Faivre L, Gorlin RJ, Wirtz MK, Godfrey M, Dagoneau N, Samples JR, Le Merrer M, Collod-Beroud G, Boileau C, Munnich A, Cormier-Daire V. 2003. In frame fibrillin-1 gene deletion in autosomal dominant Weill–Marchesani syndrome. J Med Genet 40: 3436.
  • Gambarin FI, Favalli V, Serio A, Regazzi M, Pasotti M, Klersy C, Dore R, Mannarino S, Viganò M, Odero A, Amato S, Tavazzi L, Arbustini E. 2009. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. Cardiovasc Med (Hagerstown) 10: 354362.
  • Gomez D, Coyet A, Olivier V, Jeunemaitre X, Jondeau G, Michel JB, Vranckx R. 2011. Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res 89: 446456.
  • Gott VL, Greene PS, Alejo DE, Cameron DE, Naftel DC, Miller DC, Gillinov AM, Laschinger JC, Pyeritz RE. 1999. Surgery for ascending aortic disease in Marfan patients: A multi-center study. N Engl J Med 340: 13071313.
  • Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. 2011. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332: 361365.
  • Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117121.
  • Hofmann Bowman M, Wilk J, Heydemann A, Kim G, rehman J, Lodata JA, Raman J, McNally EM. 2010. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 106: 145154.
  • Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC. 2011. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332: 358361.
  • Huang J, Davis EC, Chapman SL, Budatha M, Marmorstein LY, Word RA, Yanagisawa H. 2010. Fibulin-4 deficiency results in ascending aortic aneurysms: A potential link between abnormal smooth muscle cell phenotype and aneurysm progression. Circ Res 106: 583592.
  • Keane MG, Pyeritz RE. 2008. Medical management of Marfan syndrome. Circulation 117: 28022813.
  • Kuang SQ, Guo DC, Prakash SK, McDonald ML, Johnson RJ, Wang M, Regalado ES, Russell L, Cao JM, Kwartler C, Fraivillig K, Coselli JS, Safi HJ, Estrera AL, Leal SM, Lemaire SA, Belmont JW, Milewicz DM, GenTAC Investigators. 2011. Recurrent chromosome 16p13.1 duplications are a risk factor for aortic dissections. PLoS Genet 7(6): e1002118.
  • Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L. 2007. Rationale and design of a randomized clinical trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 154: 624631.
  • Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, Magnier S, Jondeau G. 2007. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol 99: 406409.
  • Le Goff C, Mahaut C, Wang LW, Allali S, Abhyankar A, Jensen S, Zylberberg L, Collod-Beroud G, Bonnet D, Alanay Y, Brady AF, Cordier MP, Devriendt K, Genevieve D, Kiper PÖ, Kitoh H, Krakow D, Lynch SA, Le Merrer M, Mégarbane A, Mortier G, Odent S, Polak M, Rohrbach M, Sillence D, Stolte-Dijkstra I, Superti-Furga A, Rimoin DL, Topouchian V, Unger S, Zabel B, Bole-Feysot C, Nitschke P, Handford P, Casanova JL, Boileau C, Apte SS, Munnich A, Cormier-Daire V. 2011. Mutations in the TGFβ binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am J Hum Genet 89: 714.
  • LeMaire SA, Coselli JS. 1997. Aortic root surgery in Marfan syndrome: Current practice and evolving techniques. J Card Surg 12: 137141.
  • Lindsay ME, Dietz HC. 2011. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 473: 308316.
  • Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC. 2005. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37: 275281.
  • Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Holhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM. 2010a. The revised Ghent nosology for the Marfan syndrome. J Med Genet 47: 476485.
  • Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakuri CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Keene DR, Sakai LY, Dietz HC. 2010b. Mutations in fibrillin-1 cause congenital scleroderma: Stiff skin syndrome. Sci Transl Med 2: 23ra20.
  • Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, De Backer JF, Oswald GL, Symoens S, Manouvrier S, Roberts A, Faravelli F, Greco MA, Pyeritz RE, Milewicz DM, Coucke PJ, Camreon DE, Braverman AC, Byers PH, De Paepe AM, Dietz HC. 2006. Aneurysm syndromes caused by mutations in TGF-β receptor. N Engl J Med 355: 788798.
  • Milewicz DM, Kwartler CS, Papke CL, Regalado ES, Cao J, Reid AJ. 2010. Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: Evidence for a hyperplastic vasculomyopathy. Genet Med 12: 196203.
  • Moberg K, De Nobele S, Devos D, Goetghebeur E, Segers P, Trachet B, Vervaet C, Renard M, Coucke P, Loeys B, De Paepe A, De Backer J. 2011. The Ghent Marfan Trial – A randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with beta-blockers. Int J Cardiol [Epub ahead of print].
  • Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F. 2010. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet 19: 47904798.
  • Pyeritz RE. 1989. Conference report: First International Symposium on the Marfan Syndrome. Am J Med Genet 32: 233238.
  • Pyeritz RE. 2012. Marfan syndrome and related disorders. In: Rimoin DL, Pyeritz RE, Korf BR, editors. Principles and practice of medical genetics, 6th edition. Philadelphia: Elsevier. in press.
  • Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M, COMPARE study group. 2010. Losartan therapy in adults with Marfan syndrome: Study protocol of the multi-center randomized controlled COMPARE trial. Trials 11: 3.
  • Rateri DL, Moorleghen JJ, Balakrishnan A, Owens AP 3rd, Howatt DA, Subramanian V, Poduri A, Charnigo R, Cassis LA, Daugherty A. 2011. Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor -/- mice. Circ Res 108: 574581.
  • Reed CM, Richey PA, Pulliam DA, Somes GW, Alpert BS. 1993. Aortic dimensions in tall men and women. Am J Cardiol 71: 608610.
  • Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. 1989. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 64: 507512.
  • Selamet Tierney ES, Feingold B, Printz BF, Park SC, Graham D, Kleinman CS, Mahnke CB, Timchak DM, Neches WH, Gersony WM. 2007. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 150: 7782.
  • Shores J, Berger KR, Murphy EA, Pyeritz RE. 1994. Chronic ß-adrenergic blockade protects the aorta in the Marfan syndrome: A prospective, randomized trial of propranolol. N Engl J Med 330: 13351341.
  • Tran-Fadulu V, Pannu H, Kim DH, Vick GW 3rd, Lonsford CM, Lafont AL, Boccalandro C, Smart S, Peterson KL, Hain JZ, Willing MC, Coselli JS, LeMaire SA, Ahn C, Byers PH, Milewicz DM. 2009. Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. J Med Genet 46: 607613.
  • Van Kien PK, Baux D, Pallares-Ruiz N, Baudoin C, Plancke A, Chassaing N, Collignon P, Drouin-Garraud V, Hovnanian A, Martin-Coignard D, Collod-Béroud G, Béroud C, Roux A-F, Claustres M. 2010. Missense mutations of conserved glycine residues in fibrillin-1 highlight a potential subtype of cb-EGF-like domains. Hum Mutat 31: E10211042.
  • Volguina IV, Miller DC, LeMaire SA, Palmero LC, Wang XL, Connolly HM, Sundt TM 3rd, Bavaria JE, Dietz HC, Milewicz DM, Coselli JS. 2009. Aortic Valve Operative Outcomes in Marfan Patients study group. Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: Analysis of early outcome. J Thorac Cardiovasc Surg 137: 11241132.